V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity
Junxian Ou(Southern Medical University), Qiwei Zhang(Shaanxi University of Chinese Medicine), Wendong Lan(Southern Medical University), James Chodosh(University of New Mexico), Lilian Cui, Jianguo Wu(Ministry of Education), Jing Zhang(Beihang University), Qiaoshuai Lan(Chinese University of Hong Kong), Ruixue Dai(Nanjing University of Chinese Medicine), Donald Seto(George Mason University), Gong Zhang(Shanxi Medical University), Xiaowei Wu(Zhejiang Chinese Medical University), Lu Lu(Fudan University), Shan Zhao(Chinese Academy of Tropical Agricultural Sciences), Zhonghua Zhou(Jinan University), Yi Ren(Princeton University)
Cited by 114
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)
|The Lancet|2017|856
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Etiological and epidemiological features of acute respiratory infections in China
|Nature Communications|2021|530
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
|Emerging Microbes & Infections|2021|474